RSS   Newsletter   Contact   Advertise with us
Post Online Media

AstraZeneca Q1 total revenue down 4 percent

AstraZeneca   $5.18 billion

Generic competition to cholesterol fighter Crestor and higher costs hit AstraZeneca in the first quarter, despite good sales of new drugs.

AstraZeneca said it remained on track for a promised return to sales growth in 2018.

Its latest arrivals - Imfinzi for cancer and Fasenra for severe asthma - both sold well and total product sales in the three months rose a modest 3 percent, helped by a weaker dollar.

Total revenue, however, was down 4 percent at $5.18 billion, due to investment in new drug launches and a lack of divestments compared with a year earlier. Core earnings per share, which exclude some items, slumped 51 percent to 48 cents.


What to read next

POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.